12:00 AM
 | 
Jan 16, 2001
 |  BioCentury  |  Tools & Techniques

Cor's new anti-platelet play

In the search for better oral anti-platelet drugs, oral platelet inhibition based on GPIIb/IIIa antagonists has proven to be more difficult than expected. Cor Therapeutics Inc. is one of the few remaining companies with an oral GPIIb/IIIa inhibitor, Cromafiban, in development for acute coronary syndrome or cerebrovascular accidents. But it also is hedging its bets with another mediator of platelet aggregation, P2Y12.

Last week, CORR published in Nature the cloning of P2Y12, a platelet ADP-receptor. The...

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >